XBRANS Stock Overview
Xbrane Biopharma AB (publ), a biotechnology company, develops, manufactures, and sells biosimilars.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Xbrane Biopharma AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr0.39 |
| 52 Week High | kr88.10 |
| 52 Week Low | kr30.60 |
| Beta | 1.04 |
| 1 Month Change | -58.80% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | -99.60% |
| 5 Year Change | n/a |
| Change since IPO | -98.79% |
Recent News & Updates
Recent updates
Shareholder Returns
| XBRANS | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 0% | 2.1% | 1.4% |
| 1Y | n/a | -27.7% | 1.1% |
Return vs Industry: Insufficient data to determine how XBRANS performed against the UK Biotechs industry.
Return vs Market: Insufficient data to determine how XBRANS performed against the UK Market.
Price Volatility
| XBRANS volatility | |
|---|---|
| XBRANS Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.3% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: XBRANS's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine XBRANS's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 93 | Martin Amark | www.xbrane.com |
Xbrane Biopharma AB (publ), a biotechnology company, develops, manufactures, and sells biosimilars. The company is developing Ximluci, a ranibizumab biosimilar used for the treatment of wet age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults. Its pre-clinical phase products include BIIB801, a biosimilar candidate for the treatment of rheumatoid arthritis, psoriasis, Crohn’s disease, and axial spondylitis; Xdivane for skin cancer, lung cancer, renal cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xtrudane for brain cancer, melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; and Xdarzane for multiple melanoma.
Xbrane Biopharma AB (publ) Fundamentals Summary
| XBRANS fundamental statistics | |
|---|---|
| Market cap | kr326.54m |
| Earnings (TTM) | -kr322.03m |
| Revenue (TTM) | kr238.73m |
1.4x
P/S Ratio-1.0x
P/E RatioIs XBRANS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| XBRANS income statement (TTM) | |
|---|---|
| Revenue | kr238.73m |
| Cost of Revenue | kr203.34m |
| Gross Profit | kr35.39m |
| Other Expenses | kr357.42m |
| Earnings | -kr322.03m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 16, 2024
| Earnings per share (EPS) | -0.21 |
| Gross Margin | 14.82% |
| Net Profit Margin | -134.89% |
| Debt/Equity Ratio | 102.4% |
How did XBRANS perform over the long term?
See historical performance and comparison